Boehringer Ingelheim will hire 400, invest €500M in Vienna biologics operation

Eric Palmer

Germany's has been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its revenues. After doing deals to bolster its top line, it will now spend some money on manufacturing in hopes of riding the biopharma boom to greater heights, adding about 400 jobs in the process.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS